Kamunting Street Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Kamunting Street Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-275,506	Closed	-$1.11M	–	42
2022 Q2	$1.11M	Sell	275,506 -94,122	-25%	-$356K	1.5%	15
2022 Q1	$1.83M	Sell	369,628 -58,299	-14%	-$323K	2.28%	12
2021 Q4	$2.98M	Sell	427,927 -364,497	-46%	-$2.83M	2.21%	14
2021 Q3	$7.92M	Buy	792,424 +168,223	+27%	+$1.89M	3.54%	10
2021 Q2	$8.85M	Buy	624,201 +187,894	+43%	+$2.86M	3.58%	7
2021 Q1	$7.16M	Buy	436,307 +366,806	+528%	+$7.06M	2.83%	13
2020 Q4	$1.44M	Sell	69,501 -24,086	-26%	-$358K	0.75%	33
2020 Q3	$712K	Buy	+93,587	New	+$777K	0.45%	30

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Kamunting Street Capital Management's OCUL Position: Q3 2022 in Review

Kamunting Street Capital Management sold out of Ocular Therapeutix (OCUL) in Q3 2022, closing a stake of 275,506 shares — an estimated $1.11M sold.

Kamunting Street Capital Management first reported a position in OCUL in Q3 2020 and held it in 8 quarters. The position peaked at $8.85M in Q2 2021. 130 funds tracked by Wall St. Rank hold OCUL as of Q3 2022.

Kamunting Street Capital Management reported no remaining Ocular Therapeutix position as of Q3 2022 after selling out during the quarter.
Kamunting Street Capital Management sold 275,506 Ocular Therapeutix shares in Q3 2022, an estimated $1.11M.
Kamunting Street Capital Management first reported a position in Ocular Therapeutix in Q3 2020 and held it in 8 quarters.
Kamunting Street Capital Management's Ocular Therapeutix position peaked at $8.85M in Q2 2021.
130 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2022.

Based on Kamunting Street Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.